Ghia Griarte is a Managing Partner and Co-Founder of Ponte Partners.

She was recently an appointed Board of Trustee for the City of San Jose Police and Fire Retirement Plan, a $3.6 billion public pension fund where she served in various capacities including Investment Committee Chair, Governance Chair, Audit, Joint Personnel, and Disability Committee member. She serves on the Advisory Council for the Asian Pacific Fund. Prior to Ponte she was a Managing Director at Saints Capital, a $1 billion secondary firm with global portfolio of companies across US, Europe and Asia. Prior to joining Saints in 2003, Ghia was at Centennial Ventures, a communications-focused early-stage venture capital firm. Prior to that, she was a consultant at Gemini Consulting in the Telecom, Media and Networks practice focused on major U.S., European and Israeli wireline and wireless telecommunications companies. Ghia began her career as an electrical systems engineer at Lockheed Martin and chaired the Corporate Avionics Taskforce. Ghia received an MBA from the Kellogg Graduate School of Management, an MEM from the Robert L. McCormick School of Engineering, and BS degree in Electrical Engineering and Computer Science from the University of California, Berkeley.

Lilian Shackelford Murray is a Managing Partner at Ponte. She is also a Board Director of Arcadia Biosciences (RKDA) serving on the Audit committee and chairing the Compensation committee.

Lilian has been active in the financial markets for over 35 years completing public and private transactions valued at over $3.3 billion. She founded Dovedale Investments in 2011. Previously, she was Managing Director at Saints Capital from 2002 to 2018, acquiring and managing direct secondary venture capital and private equity investments. At Saints Capital, she influenced the acquisition, disposal and management of over 150 equity investments totaling approximately $500 million. Lilian has served on the boards of various healthcare companies as director or board observer: eMedicine (sold to WebMD), ECIN (sold to AllScripts), LifeMasters, PatientKeeper (sold to HCA), Emageon (EMAG), Provation (sold to Wolters Kluwer), and Passport Health (sold to financial investors). Medical device investments included Coapt Systems (sold to Microaire Surgical), Notal Vision, MedVantx, Point Biomedical, R2 Medical (sold to Hologic), and Zonare (sold to Mindray Medical). Biotech investments included Acorda (ACOR), Biolex, Illumina (ILMN), Locus Pharmaceuticals and Raven Biotech, which was sold to MacroGenics (MGNX). She was a previously a Managing Director at Prudential Volpe Technology Group and a Managing Director at Wheat First Securities and a Senior Vice President at Dean Witter Reynolds. She began her investment banking career at E.F. Hutton. She was served on various boards including: Board of Trustees of Woodberry Forest School, Marin Community Foundation, Guide Dogs for the Blind, Episcopal Church of North America (DFMS) and University of Virginia McIntire School’s Advisory Board. Lilian received her MBA from Harvard Business School and a B.S. Commerce degree from the University of Virginia

Emmanuel Roubinowitz is a Managing Partner and co-founder of Ponte Partners.

From 2004 to 2014, Emmanuel was a Partner at Fondinvest Capital, a global primary and secondary fund of funds with $2 billion under management. Previously, Emmanuel was co-head of Technology Private equity at Nomura, the venture arm of Japan’s largest brokerage firm. Earlier in his career, Emmanuel worked at buyout firm Morgan Stanley Capital Partners and technology consulting firm Accenture. Emmanuel was one of the founders of Compagnie de Phalsbourg, a French investment company. Emmanuel has also been an advisor with Rothschild Five Arrows. Since 1989, Emmanuel has represented investors on the board of 14 companies and eight funds and directly managed six companies. Emmanuel received an MBA from Harvard Business School and a MSc. in Management from HEC Paris.